Hydrochlorothiazide/Spironolactone

氢氯噻嗪/螺内酯

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHydrochlorothiazide/Spironolactone
Drug Alias Namespironolactone and hydrochlorothiazide螺内酯/氢氯噻嗪Hydrochlorothiazide and SpironolactoneSpironolactone/hydrochlorothiazideAldactazide
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsMineralocorticoid receptor antagonists
TargetsThiazide-sensitive sodium-chloride cotransporterMineralocorticoid receptor
Therapy Area/IndicationsEdemaEssential Hypertension
Global Approved IndicationsEdemaEssential Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1961/01/27
Country/TerritoryUnited States
CombinationsYes HydrochlorothiazideSpironolactone
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsEdemaEssential Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeC03EA01
Related LinksKEGG